Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers
| Status: | Recruiting |
|---|---|
| Conditions: | Colorectal Cancer, Ovarian Cancer, Cervical Cancer, Cervical Cancer, Cervical Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Women's Studies |
| Therapuetic Areas: | Oncology, Reproductive |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 7/29/2018 |
| Start Date: | May 15, 2018 |
| End Date: | May 2021 |
| Contact: | Sung Kwon, MD |
| Email: | steve-kwonmd@mail.holyname.org |
| Phone: | 201-541-5989 |
Trial of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Primary Peritoneal Cancers and Secondary Peritoneal Cancers From Stomach, Colorectal, Appendiceal, and/or Gynecological Origins
Patients with primary peritoneal cancer or secondary peritoneal cancers from stomach,
colorectal, appendiceal, and gynecological primary origin will be screened by pathology and
staging to see if they are eligible to undergo cytoreductive surgery combined with
hyperthermic intraperitoneal chemotherapy (HIPEC).
To be eligible for the study, patients must be over 18 years of age, have appropriate
pathology and stage with disease confined to the peritoneal cavity, have a good performance
status, have laboratory values that fall within safe ranges to undergo an operation and
receive intraperitoneal chemotherapy. The chemotherapeutic agent and dose will be assigned
based on pathological diagnosis in accordance with current standard of care.
Surgery will be performed with the goal of removing all visible tumor that may require
removal of adjacent organs. Once only microscopic disease is present, the chemotherapy will
be delivered directly into the peritoneum via intraperitoneal hyperthermia and perfusion
device. This will continue for 90 minutes.
Patients will be followed for tumor response, survival, toxicity, complications, quality of
life, and tumor markers. They will have regular follow up visits with the surgeon, undergo
routine surveillance imagings, and receive follow up phone calls periodically.
colorectal, appendiceal, and gynecological primary origin will be screened by pathology and
staging to see if they are eligible to undergo cytoreductive surgery combined with
hyperthermic intraperitoneal chemotherapy (HIPEC).
To be eligible for the study, patients must be over 18 years of age, have appropriate
pathology and stage with disease confined to the peritoneal cavity, have a good performance
status, have laboratory values that fall within safe ranges to undergo an operation and
receive intraperitoneal chemotherapy. The chemotherapeutic agent and dose will be assigned
based on pathological diagnosis in accordance with current standard of care.
Surgery will be performed with the goal of removing all visible tumor that may require
removal of adjacent organs. Once only microscopic disease is present, the chemotherapy will
be delivered directly into the peritoneum via intraperitoneal hyperthermia and perfusion
device. This will continue for 90 minutes.
Patients will be followed for tumor response, survival, toxicity, complications, quality of
life, and tumor markers. They will have regular follow up visits with the surgeon, undergo
routine surveillance imagings, and receive follow up phone calls periodically.
Peritoneal carcinomatosis can be caused by primary peritoneal cancers and secondary
peritoneal spread from stomach, colorectal, appendiceal, and/or gynecological cancers.
Combined presentation of patients with peritoneal carcinomatosis make up about 67,000 new
cancer diagnoses each year. Of these cases, about 25,000 patients are estimated to be
candidates for cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy
(HIPEC); however, in 2009 only five percent of these patients received such treatment.
Alternative therapies to cytoreductive surgery and HIPEC are few. They include surgical
treatments with cytoreduction alone which are palliative in nature and inadequate to manage
the disease, radiation which is limited in regard to tumors disseminated throughout abdominal
cavity, systemic chemotherapy which has poor penetration into the peritoneum. Intraperitoneal
chemotherapy via indwelling peritoneal catheter is limited due to port infections, toxicity,
and unequal distribution in the abdominal cavity.
For patients whose disease is limited to the peritoneal cavity, multi-modality treatment with
cytoreductive surgery followed by intraoperative HIPEC can deliver chemotherapy directly to
microscopic tumors at a higher concentration than is tolerated systemically. It causes
disruption of cell membranes and induces apoptosis. Moreover when intraperitoneal
chemotherapy is given at a higher temperature, it has a selective lethal effect on cancer
cells secondary to improved tissue absorption. The typical side effects of systemic
chemotherapy are also minimized with HIPEC.
HIPEC is given intraoperatively in one treatment setting after all visible disease has been
resected (i.e., cytoreductive surgery). The goal of cytoreductive surgery is to leave behind
only microscopic disease and may require removal of adjacent organs. HIPEC is then delivered
via tubings with temperature probes that are placed in the intraperitoneal cavity. The skin
is then temporarily closed and the tubings are connected to a intraperitoneal hyperthermia
and perfusion device that delivers sterile solution with chemotherapy into the abdomen. The
device heats and circulates the chemotherapy for 90 minutes. After HIPEC is completed,
abdomen is reopened and copiously irrigated. Surgical reconstruction with any removed organs
(such as bowel) and fascial/skin closure are the final steps.
Previous studies have shown conflicting results on survival benefit for patients with some of
the aforementioned secondary peritoneal cancers who have undergone cytoreductive surgery and
HIPEC. This study is an outcomes based study that seeks to look at the impact of HIPEC on
overall survival and recurrence-free survival.
peritoneal spread from stomach, colorectal, appendiceal, and/or gynecological cancers.
Combined presentation of patients with peritoneal carcinomatosis make up about 67,000 new
cancer diagnoses each year. Of these cases, about 25,000 patients are estimated to be
candidates for cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy
(HIPEC); however, in 2009 only five percent of these patients received such treatment.
Alternative therapies to cytoreductive surgery and HIPEC are few. They include surgical
treatments with cytoreduction alone which are palliative in nature and inadequate to manage
the disease, radiation which is limited in regard to tumors disseminated throughout abdominal
cavity, systemic chemotherapy which has poor penetration into the peritoneum. Intraperitoneal
chemotherapy via indwelling peritoneal catheter is limited due to port infections, toxicity,
and unequal distribution in the abdominal cavity.
For patients whose disease is limited to the peritoneal cavity, multi-modality treatment with
cytoreductive surgery followed by intraoperative HIPEC can deliver chemotherapy directly to
microscopic tumors at a higher concentration than is tolerated systemically. It causes
disruption of cell membranes and induces apoptosis. Moreover when intraperitoneal
chemotherapy is given at a higher temperature, it has a selective lethal effect on cancer
cells secondary to improved tissue absorption. The typical side effects of systemic
chemotherapy are also minimized with HIPEC.
HIPEC is given intraoperatively in one treatment setting after all visible disease has been
resected (i.e., cytoreductive surgery). The goal of cytoreductive surgery is to leave behind
only microscopic disease and may require removal of adjacent organs. HIPEC is then delivered
via tubings with temperature probes that are placed in the intraperitoneal cavity. The skin
is then temporarily closed and the tubings are connected to a intraperitoneal hyperthermia
and perfusion device that delivers sterile solution with chemotherapy into the abdomen. The
device heats and circulates the chemotherapy for 90 minutes. After HIPEC is completed,
abdomen is reopened and copiously irrigated. Surgical reconstruction with any removed organs
(such as bowel) and fascial/skin closure are the final steps.
Previous studies have shown conflicting results on survival benefit for patients with some of
the aforementioned secondary peritoneal cancers who have undergone cytoreductive surgery and
HIPEC. This study is an outcomes based study that seeks to look at the impact of HIPEC on
overall survival and recurrence-free survival.
Inclusion Criteria:
Age >18
Diagnosis at the time of resection or on frozen section of:
- recurrent or primary stomach, colorectal or appendiceal cancer with regional spread
that is confined to the peritoneal cavity
- primary peritoneal cancer
- ovarian cancer stage IC or higher
- uterine or cervical cancer stage IIA or higher with recurrence confined to the
peritoneum
- fallopian tube cancer stage III or recurrence confined to the peritoneum ECOG
performance status of 0,1, or 2
Lab values:
- absolute neutrophil count >1500
- platelets >100,000
- creatinine less than or equal to 2.0mg/dL
- bilirubin less than or equal to 1.5 times the upper limit of normal
- SGOT and alkaline phosphatase less than or equal to 2.5 times the upper limit of
normal
- patients of childbearing age must have a negative serum pregnancy test and be using an
effective form of contraception
Exclusion Criteria:
- Extra-peritoneal disease or unresectable disease
- Any known sensitivity to the chemotherapeutic agents used in the study
- Significant medical comorbidities that would prevent the patient from being able to
complete the protocol (at discretion of investigator)
- Patients with gynecological malignancy who desire future fertility
- An informed consent cannot be obtained from the patient or power of attorney
We found this trial at
1
site
Teaneck, New Jersey 07666
Principal Investigator: Sung Kwon, MD
Phone: 201-541-5989
Click here to add this to my saved trials
